ArticleArthritis research & therapy2020

Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.

Irini Genitsaridi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.